THE PHARMACEUTICAL-INDUSTRY VIEWPOINT

Authors
Citation
Hf. Marlow, THE PHARMACEUTICAL-INDUSTRY VIEWPOINT, Cardiology, 85, 1994, pp. 102-112
Citations number
23
Categorie Soggetti
Cardiac & Cardiovascular System
Journal title
ISSN journal
00086312
Volume
85
Year of publication
1994
Supplement
1
Pages
102 - 112
Database
ISI
SICI code
0008-6312(1994)85:<102:TPV>2.0.ZU;2-F
Abstract
The health of its people is a matter of importance for any responsible government. This is primarily achieved through ensuring adequate stan dards of nutrition, housing, and hygiene. The government has additiona lly to ensure the provision of an effective and affordable health care system. This must deliver adequate medical resources that are readily available for those who fall ill. Cardiovascular disease is the major cause of mortality in the Western world. Thus, it is incumbent on the government to provide health care for those who suffer from cardiovas cular disease. There is a further obligation to promote a healthy life -style in the community by providing dietary advice and discouraging a voidable risk factors (e.g., smoking). Life-style changes are not easy and may be insufficient to beneficially influence the risk factors fo r cardiovascular disease. The pharmaceutical industry, therefore, play s an integral role in health care delivery by providing doctors with t he medicines to manage those patients who suffer from cardiovascular d isease, for whom life-style changes have not provided the answer. In m ost European countries, the pharmaceutical industry operates within ti ght government regulatory confines which define efficacy and safety of medicines. In those countries where there is a socialized health care policy, the prices of medicines are regulated by the government. Thus government intervention in most European countries is a fact of life for the industry, and the manner in which it exercises its powers will have a critical effect on whether the intervention is a help or hindr ance.